Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | 08/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -185.25% | 9.89% | 11.62% | 51.50% | 72.41% |
| Total Depreciation and Amortization | -25.00% | -25.00% | -25.00% | -92.31% | -33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 148.32% | 2.56% | 374.75% | -64.18% | -138.20% |
| Change in Net Operating Assets | 289.47% | 230.72% | 115.10% | 10.79% | 110.02% |
| Cash from Operations | 87.12% | 60.66% | 61.22% | 116.04% | 92.62% |
| Capital Expenditure | 2.19% | 15.41% | 10.29% | 29.36% | 18.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 2.19% | 15.41% | 10.29% | 12.90% | 18.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -65.85% | -- | -58.86% | -- | -98.69% |
| Repurchase of Common Stock | -- | -43.59% | -- | -197.62% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 60.16% | -- | 100.00% |
| Cash from Financing | 231.71% | -139.29% | -58.62% | 129.17% | -98.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.93% | 55.37% | -59.92% | 100.06% | -621.02% |
